Logo Image
News|Articles|December 2, 2024

World Health Organization Adds New Mpox Vaccine to Emergency Use Listing

This comes after Japan recently announced it will donate over 3 million doses of the mpox vaccine, LC16m8 to a country in Africa.

The World Health Organization (WHO) has added another mpox vaccine, LC16m8, to the list of available vaccines through its Emergency Use Listing (EUL). LC16m8 was developed and manufactured by KM Biologics in Japan.1

“WHO emergency use listing of the LC16m8 vaccine against mpox marks a significant step in our response to the current emergency, providing a new option to protect all populations, including children,” Yukiko Nakatani, MD, PhD, WHO assistant director-general for Access to Medicines and Health Products, said in a statement. “Vaccines are one of the important tools to help contain the outbreak as part of a comprehensive response strategy that also includes improved testing and diagnosis, treatment and care, infection prevention control, and engagement and education within affected communities.”1

The WHO’s Technical Advisory Group (TAG) for Emergency Use Listing (EUL) of vaccines convened to discuss the outcome of the LC16m8 vaccine review, including the product and programmatic suitability assessments. The TAG recommended the vaccine for use in individuals over 1 year of age as a single dose vaccine, via a multiple puncture technique using a bifurcated needle.1

The WHO Strategic Advisory Group of Experts (SAGE) on Immunization reviewed available evidence and recommended the use of LC16m8 vaccine in outbreak settings in children and others with a documented high-risk of exposure to mpox.1

This recent announcement coincides with the Government of Japan announcing it was going to donate 3.05 million doses of the LC16m8 vaccine, along with specialized inoculation needles, to the Democratic Republic of the Congo, which is one of the hardest hit countries of the recent ongoing outbreaks in Africa. The LC16m8 vaccine has been used in Japan during previous mpox outbreaks and was shown to be safe and effective, including in people with well-controlled HIV.1

What You Need to Know

The World Health Organization (WHO) approved the LC16m8 vaccine for emergency use against Mpox, marking it as a critical tool in outbreak containment.

Japan pledged to donate 3.05 million doses of the LC16m8 vaccine to the Democratic Republic of the Congo, a region severely impacted by ongoing mpox outbreaks.

The Mpox outbreaks, declared global and continental emergencies by the WHO and Africa CDC, have triggered robust responses, including the prequalification of the MVA-BN vaccine last year for use in individuals aged 12 and older.

Last August, the Africa Centers for Disease Control and Prevention (Africa CDC) declared the ongoing mpox outbreak a Public Health Emergency of Continental Security, and during that same time period, the World Health Organization declared the mpox outbreaks in Congo and elsewhere in Africa a global emergency. 2-3

In previous reporting by Contagion, the first case in the US was confirmed last month. The person infected with mpox had traveled to areas where transmission had been ongoing.

In terms of the person’s condition, the individual had been receiving care in the US and was isolating from others. The patient, who has no underlying health conditions, has not had any severe manifestations of disease, and symptoms are improving, according to a Centers for Disease Control and Prevention statement. The federal agency said it is working closely with the local and state health authorities to investigate the circumstances surrounding this case and to prevent spread of the virus.4

Back in October, WHO prequalified another mpox immunization, the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine and expanded its indication to include use in individuals aged 12 years and older.1

References
1.WHO adds LC16m8 mpox vaccine to Emergency Use Listing. WHO press release. November 19, 2024. Accessed December 2, 2024. https://www.who.int/news/item/19-11-2024-who-adds-lc16m8-mpox-vaccine-to-emergency-use-listing
2. Africa CDC Declares Mpox A Public Health Emergency of Continental Security, Mobilizing Resources Across the Continent. Africa CDC. August 13, 2024. August 14, 2024.
https://africacdc.org/news-item/africa-cdc-declares-mpox-a-public-health-emergency-of-continental-security-mobilizing-resources-across-the-continent
3. Cheng M. WHO declares mpox outbreaks in Africa a global health emergency as a new form of the virus spreads. AP News. August 14, 2024. Accessed August 14, 2024. https://apnews.com/article/who-mpox-africa-health-emergency-cc9bdf31b49d06bec5efd44fb55d5e42
4.First Case of Clade I Mpox Diagnosed in the United States. CDC. November 18, 2024. Accessed December 2, 2024.
https://emergency.cdc.gov/han/2024/han00519.asp

Related to this article

View more
FAQ: Rising Rabies Exposure Calls PEP Decisions Back in Focus
FAQ: Rising Rabies Exposure Calls PEP Decisions Back in Focus
Following World Rabies Day and a CDC health advisory on a 17% rise in exposure-related calls, Rodney E. Rohde, PhD, explains what the increase means, what people should do when they have an animal bite or scratch, and how clinicians should assess risk and administer post-exposure prophylaxis (PEP).
Read more
Ebola and the Ongoing Tale of US Failures
Ebola and the Ongoing Tale of US Failures
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
Read more
CDC Responds to Surge in Rabies Exposures
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
Read more